MedTrace Logo

Niclosamide With Etanercept in Rheumatoid Arthritis

NCT03160001 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2018-12-12

No results posted yet for this study

Summary

Assessment of the adjuvant use Niclosamide With Etanercept in Rheumatoid Arthritis

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

DRUG

Placebo

Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily

DRUG

Niclosamide

Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks

DRUG

Etanercept

Etanercept 50mg weekly

Sponsors & Collaborators

  • Faiq Gorial

    lead OTHER

Principal Investigators

  • Ahmed S Mahmood, MSc · Baghdad Teaching Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2018-08-15
Completion
2018-12-10
FDA Drug
Yes

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03160001 on ClinicalTrials.gov